What to Know About Ozempic and Gastroparesis in New York
From General Health Awareness to Specific Legal Concerns
If you or someone you know is experiencing persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be concerned about gastroparesis. This condition, which affects stomach muscle function, has been increasingly reported among users. Building on decades of medical research linking certain medications to digestive complications, this page explains what gastroparesis is, how it relates to Ozempic, and when evaluation is typically recommended.
The Link Between Ozempic and Gastroparesis
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes mellitus. Its pharmacological action includes slowing gastric emptying, which is a known mechanism that can contribute to gastrointestinal adverse effects. Among these, gastroparesis—a condition characterized by delayed gastric emptying in the absence of mechanical obstruction—has emerged as a significant concern. Clinical presentation of gastroparesis includes nausea, vomiting, early satiety, postprandial fullness, abdominal pain, and bloating. Diagnosis typically involves gastric emptying scintigraphy or breath tests to confirm delayed emptying. The link between Ozempic and gastroparesis is supported by its mechanism of action and reported adverse effects. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients include nausea (15.8% for 0.5 mg, 20.3% for 1 mg), vomiting (5.0% for 0.5 mg, 9.2% for 1 mg), diarrhea (8.5% for 0.5 mg, 8.8% for 1 mg), abdominal pain (7.3% for 0.5 mg, 5.7% for 1 mg), and constipation (5.0% for 0.5 mg, 3.1% for 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms overlap with those of gastroparesis, and the dose-dependent increase in gastrointestinal adverse reactions suggests a mechanistic pathway where Ozempic-induced delayed gastric emptying may lead to or exacerbate gastroparesis.
Postmarketing Evidence and Warning Adequacy
Postmarketing reports further highlight the risk of retained gastric contents. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This indicates that Ozempic can cause significant delays in gastric emptying, which is a hallmark of gastroparesis. The available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking Ozempic, including whether modifying preoperative fasting recommendations or temporarily discontinuing Ozempic could reduce the incidence of retained gastric contents (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This underscores the clinical significance of gastroparesis as an adverse effect. Regarding the adequacy of warnings, the prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions and postmarketing reports of pulmonary aspiration, but it does not explicitly list gastroparesis as a specific adverse reaction. The label notes that gastrointestinal adverse reactions occurred more frequently with Ozempic than placebo and that discontinuation due to these reactions was higher (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the label does not provide specific guidance on monitoring for gastroparesis or on the risk of developing this condition. This may be considered inadequate for patients who develop severe symptoms. Additionally, hypersensitivity reactions such as anaphylaxis and angioedema have been reported with Ozempic and other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but these are distinct from gastroparesis.
Statute of Limitations for Ozempic Claims in New York
For affected patients in New York, attorney-related considerations include the statute of limitations for product liability claims. In New York, the statute of limitations for personal injury claims is generally three years from the date of injury, but for medical malpractice or product liability, it may vary. The timeline between exposure to Ozempic and documented harm is critical. Patients may develop gastroparesis symptoms weeks to months after starting Ozempic, and diagnosis may be delayed. The statute of limitations typically begins when the injury is discovered or should have been discovered. Given that Ozempic is a chronic medication, patients may need to document the onset of symptoms, medical evaluations, and any discontinuation of the drug. Legal counsel should be sought promptly to assess individual circumstances. In summary, Ozempic is associated with gastrointestinal adverse reactions that can include gastroparesis, supported by clinical trial data and postmarketing reports of retained gastric contents. The adequacy of warnings may be insufficient for patients who develop severe gastroparesis. Patients in New York should be aware of the statute of limitations and seek legal advice if they have experienced harm.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for an Ozempic gastroparesis lawsuit in New York?
In New York, the statute of limitations for personal injury claims, including product liability, is generally three years from the date of injury. However, for medical malpractice or product liability, the timeline may vary. The clock typically starts when the injury is discovered or should have been discovered. It is crucial to consult an attorney promptly to evaluate your specific case.
How does Ozempic cause gastroparesis?
Ozempic (semaglutide) slows gastric emptying as part of its mechanism of action. This can lead to delayed gastric emptying, which is the hallmark of gastroparesis. Clinical trials show higher rates of gastrointestinal adverse reactions in Ozempic users compared to placebo, including nausea, vomiting, and abdominal pain, which overlap with gastroparesis symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.